Nexus between hepatic enzyme modulation and cancer

Cinoy Maliakal, Hima Pius, Chris M. Lee, Umesh Tanaji Sankpal

Research output: Contribution to journalArticle

Abstract

The risk of developing cancer caused by environmental carcinogens lies in the balance between phase I carcinogen-activating enzymes and phase II detoxifying enzymes. Potentially genotoxic chemicals to which we are exposed to may require metabolic activation to exhibit their mutagenic and carcinogenic effects. Most of the enzyme systems, involved in carcinogen bioactivation, are concentrated in liver, but many extrahepatic organs and tissues have appreciable quantities of such enzymes. Most chemical carcinogens are activated in humans by specific cytochrome P450 (CYP) species, mainly CYP1A1, CYP1A2, CYP2E, and CYP3A. Activation of chemical carcinogens follows various metabolic pathways. The difference could range from only a single oxidation step or several sequential enzymatic steps. Polymorphic differences in carcinogen metabolism may result in difference in carcinogen risk since fast activators and/or slow detoxifiers may have higher steady state tissue concentration of the causative agent than slow activator and/or fast detoxifiers. Cancer prevention through better diet and nutrition has received considerable attention in the past and continues to show promise even today". It has become increasingly apparent that adopting a diet may allow reduction in cancer incidence worldwide by functioning as inhibitors of tumor initiation, promotion, and progression, which may be mediated by either selective induction or inhibition of the hepatic xenobiotic metabolizing enzymes.

Original languageEnglish
Pages (from-to)1372-1382
Number of pages11
JournalCurrent Trends in Biotechnology and Pharmacy
Volume5
Issue number4
StatePublished - 1 Oct 2011

Fingerprint

Carcinogens
Liver
Enzymes
Neoplasms
Environmental Carcinogens
Diet
Cytochrome P-450 CYP3A
Cytochrome P-450 CYP1A2
Cytochrome P-450 CYP1A1
Xenobiotics
Metabolic Networks and Pathways
Cytochrome P-450 Enzyme System
Nexus
Incidence

Keywords

  • Bioactivation
  • Cancer prevention
  • Carcinogens
  • Cytochrome P450
  • Hepatic enzymes

Cite this

Maliakal, Cinoy ; Pius, Hima ; Lee, Chris M. ; Sankpal, Umesh Tanaji. / Nexus between hepatic enzyme modulation and cancer. In: Current Trends in Biotechnology and Pharmacy. 2011 ; Vol. 5, No. 4. pp. 1372-1382.
@article{bece1866ee6249e7b7230e067ff85ce7,
title = "Nexus between hepatic enzyme modulation and cancer",
abstract = "The risk of developing cancer caused by environmental carcinogens lies in the balance between phase I carcinogen-activating enzymes and phase II detoxifying enzymes. Potentially genotoxic chemicals to which we are exposed to may require metabolic activation to exhibit their mutagenic and carcinogenic effects. Most of the enzyme systems, involved in carcinogen bioactivation, are concentrated in liver, but many extrahepatic organs and tissues have appreciable quantities of such enzymes. Most chemical carcinogens are activated in humans by specific cytochrome P450 (CYP) species, mainly CYP1A1, CYP1A2, CYP2E, and CYP3A. Activation of chemical carcinogens follows various metabolic pathways. The difference could range from only a single oxidation step or several sequential enzymatic steps. Polymorphic differences in carcinogen metabolism may result in difference in carcinogen risk since fast activators and/or slow detoxifiers may have higher steady state tissue concentration of the causative agent than slow activator and/or fast detoxifiers. Cancer prevention through better diet and nutrition has received considerable attention in the past and continues to show promise even today{"}. It has become increasingly apparent that adopting a diet may allow reduction in cancer incidence worldwide by functioning as inhibitors of tumor initiation, promotion, and progression, which may be mediated by either selective induction or inhibition of the hepatic xenobiotic metabolizing enzymes.",
keywords = "Bioactivation, Cancer prevention, Carcinogens, Cytochrome P450, Hepatic enzymes",
author = "Cinoy Maliakal and Hima Pius and Lee, {Chris M.} and Sankpal, {Umesh Tanaji}",
year = "2011",
month = "10",
day = "1",
language = "English",
volume = "5",
pages = "1372--1382",
journal = "Current Trends in Biotechnology and Pharmacy",
issn = "0973-8916",
publisher = "Association of Biotechnology and Pharmacy",
number = "4",

}

Nexus between hepatic enzyme modulation and cancer. / Maliakal, Cinoy; Pius, Hima; Lee, Chris M.; Sankpal, Umesh Tanaji.

In: Current Trends in Biotechnology and Pharmacy, Vol. 5, No. 4, 01.10.2011, p. 1372-1382.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nexus between hepatic enzyme modulation and cancer

AU - Maliakal, Cinoy

AU - Pius, Hima

AU - Lee, Chris M.

AU - Sankpal, Umesh Tanaji

PY - 2011/10/1

Y1 - 2011/10/1

N2 - The risk of developing cancer caused by environmental carcinogens lies in the balance between phase I carcinogen-activating enzymes and phase II detoxifying enzymes. Potentially genotoxic chemicals to which we are exposed to may require metabolic activation to exhibit their mutagenic and carcinogenic effects. Most of the enzyme systems, involved in carcinogen bioactivation, are concentrated in liver, but many extrahepatic organs and tissues have appreciable quantities of such enzymes. Most chemical carcinogens are activated in humans by specific cytochrome P450 (CYP) species, mainly CYP1A1, CYP1A2, CYP2E, and CYP3A. Activation of chemical carcinogens follows various metabolic pathways. The difference could range from only a single oxidation step or several sequential enzymatic steps. Polymorphic differences in carcinogen metabolism may result in difference in carcinogen risk since fast activators and/or slow detoxifiers may have higher steady state tissue concentration of the causative agent than slow activator and/or fast detoxifiers. Cancer prevention through better diet and nutrition has received considerable attention in the past and continues to show promise even today". It has become increasingly apparent that adopting a diet may allow reduction in cancer incidence worldwide by functioning as inhibitors of tumor initiation, promotion, and progression, which may be mediated by either selective induction or inhibition of the hepatic xenobiotic metabolizing enzymes.

AB - The risk of developing cancer caused by environmental carcinogens lies in the balance between phase I carcinogen-activating enzymes and phase II detoxifying enzymes. Potentially genotoxic chemicals to which we are exposed to may require metabolic activation to exhibit their mutagenic and carcinogenic effects. Most of the enzyme systems, involved in carcinogen bioactivation, are concentrated in liver, but many extrahepatic organs and tissues have appreciable quantities of such enzymes. Most chemical carcinogens are activated in humans by specific cytochrome P450 (CYP) species, mainly CYP1A1, CYP1A2, CYP2E, and CYP3A. Activation of chemical carcinogens follows various metabolic pathways. The difference could range from only a single oxidation step or several sequential enzymatic steps. Polymorphic differences in carcinogen metabolism may result in difference in carcinogen risk since fast activators and/or slow detoxifiers may have higher steady state tissue concentration of the causative agent than slow activator and/or fast detoxifiers. Cancer prevention through better diet and nutrition has received considerable attention in the past and continues to show promise even today". It has become increasingly apparent that adopting a diet may allow reduction in cancer incidence worldwide by functioning as inhibitors of tumor initiation, promotion, and progression, which may be mediated by either selective induction or inhibition of the hepatic xenobiotic metabolizing enzymes.

KW - Bioactivation

KW - Cancer prevention

KW - Carcinogens

KW - Cytochrome P450

KW - Hepatic enzymes

UR - http://www.scopus.com/inward/record.url?scp=80054703114&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:80054703114

VL - 5

SP - 1372

EP - 1382

JO - Current Trends in Biotechnology and Pharmacy

JF - Current Trends in Biotechnology and Pharmacy

SN - 0973-8916

IS - 4

ER -